Business Wire India

Dettol, India’s leading germ protection brand, launches a heartfelt new campaign for its iconic Dettol Antiseptic Liquid, with an emotion-led narrative that strengthens the brand’s connection with families while highlighting its unmatched protection. Built on the universal truth of a mother’s instinctive care, the campaign brings to life the thought: “Nothing protects like Mom & Dettol.”

 

For generations, Dettol has been more than just a product, it has been a reassuring presence in moments of vulnerability. The new film captures this emotional essence through a tender moment set in the lively chaos of a shaadi ka ghar. Amid the celebrations, a young boy hurts himself and hides his injury from others, putting on a brave face. But the moment he reaches his mother, she instinctively senses something is wrong. As she tends to his wound with Dettol Antiseptic Liquid, his guard drops, revealing his pain, only to be followed by a touching role reversal, where he comforts her instead.

 

The film concludes with the message: “Apnon ki suraksha ka mazboot sahara.” It reaffirms Dettol’s timeless place in Indian homes, standing beside mothers in moments where love is instinctive, and protection is assured.

 

The film is brought to life with the concept and film written by Prasoon Joshi, original track by Vishal Khurana, sung by Javed Ali, lyrics by Prasoon Joshi, direction by Amit Sharma, weaving together emotion, culture, and authenticity.

 

Commenting on the launch, Gaurav Jain, EVP Regional Director, Reckitt – South Asia, said, “At Reckitt, we believe our responsibility goes far beyond delivering products—we are here to build a world where people feel safe, protected and empowered to care for one another. Dettol stands at the heart of this mission. Its legacy spans generations, becoming a silent but steadfast companion in homes across India. It is a brand that shows up not only in moments of need, but in moments of emotion, times when a mother’s instinct takes over, when a child’s tears are hidden behind bravery, when protection is both physical and deeply personal. This campaign encapsulates that delicate, human truth: a mother senses hurt even before it is spoken, and Dettol strengthens her ability to respond with care and confidence. Together, a mother’s instinct and Dettol’s protection create a bond that generations have trusted and will continue to trust for years to come.”

 

Prasoon Joshi, Chairman, Omnicom India, said, “I really enjoyed writing this simple, storytelling-led piece of brand communication. Dettol has always stood for care and protection. Because when a child is hurt, no matter how big or small, the first instinct is to reach for their mother, their ultimate safe space. And in that moment, the mother turns to Dettol, something she trusts to protect what matters most. This is the bond we wanted to bring alive. A bond of quiet care, instinctive love, and unwavering trust, something we never really outgrow. This would not have been possible without a committed team, at Reckitt, and at Chrome, Amit Sharma’s sensitive direction, along with the performances and the music brought alive by Vishal Khurana and Javed Ali.”

 

As the heart of the Dettol portfolio, Dettol Antiseptic Liquid continues to offer unmatched protection for cuts and wounds, reinforcing its role in safeguarding families across generations. Whether it’s a scraped knee, a sudden fall, or a quiet, hidden tear, Dettol has stood by mothers as the strong partner that helps them protect the ones they love most.

 

Through this campaign, Dettol reaffirms its enduring place in Indian households, standing shoulder to shoulder with mothers in life’s most vulnerable moments, where care is instinctive and protection is unmatched.

 

Link to TVC: https://youtu.be/UqeskegtsIw

 

Written & Conceptualised by Prasoon Joshi (Chairman- Omnicom India)

Agency: McCann, Gurgaon

Creative Team: Prasoon Joshi, Anand Bhushan, Ashish Nath, Rajesh Chandra

Account management: Srijib Malik, Tanisha Sharma, Saumya Sharma

Films Team: Jeet Kalra

Planning: Sumeer Mathur, Madhavi Karunakaram Guha, Aditi Jain

Director: Amit Sharma

Production house: Chrome Pictures

Business Wire India

 

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced a strategic partnership with Sihuan Pharmaceutical Holdings Group Ltd. (Sihuan Pharmaceutical; HKEX: 00460).

 

Under the agreement, both parties will combine Biocytogen’s leading fully human antibody discovery platform with Sihuan Pharmaceutical’s extensive capabilities in drug development, manufacturing, and commercialization. The collaboration will focus on advancing innovative therapies across multiple disease areas, including weight loss, leveraging complementary strengths to drive synergies and establish a long-term strategic partnership.

 

 

Sihuan Pharmaceutical highly values the strength of Biocytogen’s technology platforms. In this collaboration, Biocytogen will leverage its integrated platforms, including proprietary target-humanized mouse models and in vivo efficacy systems, as well as its AI-driven antibody discovery platform built on real human antibody sequences, to support the development of novel antibody therapeutics. By combining the complementary strengths of both parties, the partnership aims to accelerate the advancement of promising molecules toward clinical and commercial success.

 

 

Dr. Yuelei Shen, President and CEO of Biocytogen, stated: “We are pleased to establish this strategic partnership with Sihuan Pharmaceutical. Leveraging our proprietary platforms, Biocytogen has built a comprehensive pipeline of next-generation therapeutic modalities, including bispecific and multispecific antibodies, ADCs, VHHs, and TCR-based therapeutics. This collaboration will further expand our joint efforts across diverse disease areas and further demonstrate strong industry recognition of our technology platforms.”

 

 

About Biocytogen

 

 

Biocytogen (SSE: 688796; HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen has established a dual-engine platform combining a fully human antibody library with an extensive target-humanized mouse model portfolio, enabling a systematic approach to accelerating global drug discovery and development.

 

 

Biocytogen has independently developed its proprietary RenMice^® (RenMab^®/RenLite^®/RenNano^®/RenTCR™/RenTCR mimic™) platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, hu-VHH discovery, and TCR mimic antibody discovery, and has established a sub-brand, RenSuper™ Biologics, to explore global partnerships for an off-the-shelf library of >1,000,000 fully human antibody sequences against over 1000 targets for worldwide collaboration. As of December 31, 2025, more than 350 agreements for therapeutic antibodies and clinical assets—spanning co-development, out-licensing, and transfers—have been established globally, including landmark partnerships with leading multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company’s sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen, Jiangsu, Shanghai), the USA (Boston, San Francisco, San Diego), and Germany (Heidelberg). For more information, please visit https://biocytogen.com.

 

 

About Sihuan Pharmaceutical

 

 

Founded in 2001 and listed on the Main Board of The Stock Exchange of Hong Kong Limited in 2010, Sihuan Pharmaceutical is an international medical aesthetic and pharmaceutical company led by innovation, with an independent and leading research and development technology platform, a rich global product pipeline, strong product registration capability, a full dosage form production platform with high efficiency and low cost and a mature and excellent sales system. Adhering to the overall strategic goal for the “full promotion of a two-wheel drive strategy of its medical aesthetics and biopharmaceutical businesses”, Sihuan Pharmaceutical endeavors to build itself into a leading medical aesthetics and biopharmaceutical company in China.

 

 

 

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260401580773/en/

 

Business Wire India

The Net Green Foundation High Impact Sustainability Dialogue & Earth Awards 2026, organised at UNESCO House, New Delhi, successfully brought together policymakers, sustainability leaders, industry experts, academicians, civil society representatives, and young innovators. The event witnessed the participation of over 125 distinguished attendees.

During the ceremony, the Net Green Foundation Earth Awards 2026 honoured more than 25 outstanding individuals, organisations, and initiatives for their remarkable contributions to environmental conservation, climate action, water sustainability, clean energy, circular economy, and community-driven sustainability.

The event was supported by key government institutions, including the Ministry of Environment, Forest and Climate Change, the Ministry of Jal Shakti, and the Department of Water Resources, River Development and Ganga Rejuvenation, Government of India, Uttar Pradesh Industrial Development Authority, along with the national movement Mission LiFE.

Shri Sardar Manjinder Singh Sirsa, Hon’ble Minister of Industries, Food & Supplies and Environment, Forest & Wildlife, Government of NCT of Delhi was Chief guest of the event, while Shri Acharya Balkrishna ji was the Guest of Honour. Natural Sciences Programme Specialist at UNESCO India, Dr Benno Böer, was the special guest at the event.

Earlier, the programme opened with the Welcome Address by Ms Surbhi Gupta, Director, Net Green Foundation. Ms Neha Edwin, Senior Vice President, Net Green Foundation, delivered the Opening Address. Mr Umesh Kumar Sharma, Director and Editor-in-Chief, and Ms Vaanii Hiremath, Director, Net Green Foundation, were also present on the occasion.

Domain experts and thought leaders have underlined urgency for action toward building sustainable and climate-resilient communities to ensure a sustainable future. The experts have also pointed out the importance of collective action in protecting ecosystems.

Discussing sustainability issues at the Net Green Foundation High-Impact Knowledge Exchange & Earth Awards 2026 at UNESCO House, here, a panel moderated by Dr Rajeev Jindal, Professor of Practice, Department of Design, IIT Kanpur, explored various issues including corporate sustainability leadership, responsible infrastructure development, water stewardship, and the role of financial institutions in enabling green initiatives.

Another panel discussed issues related to community engagement, climate leadership, environmental education, and the importance of collective action in protecting ecosystems. This was moderated by Dr Lipika Sharma, Senior Consultant (Gender & Climate Expert) – UN Women.

Eminent panelists included Mr Debasis Satapathy, Chief General Manager (HRM), NBCC Limited; Mr Kamal Chugh, Head – Government & Institutional Business (North India), Federal Bank Limited; Dr Santanu Basu, Project Director – Harit, HCL Foundation; and Ms Rajni Dhiman, Head of Department- Water, Ramboll India Pvt. Ltd. Ms Tanish Maheshwari, Head – Communications & Advocacy, DLF Foundation, Prof. Vivek Kumar, Professor, IIT Delhi, Prof. C.R. Babu, Professor Emeritus, Centre for Environmental Management of Degraded Ecosystems (CEMDE), University of Delhi and Swami Prem Parivartan (Peepal Baba), Founder, Give Me Trees Trust.

A number of institutions including the Federal Bank, Zee, South Eastern Coalfields Limited, Radha TMT, and SUEZ India Foundation, were partners in the initiative.

The event reaffirmed the Foundation’s commitment to building a powerful ecosystem that celebrates sustainability leadership, encourages innovation, and fosters partnerships for a greener and more resilient future. Through such initiatives, the Foundation continues to create platforms that inspire action, innovation, and measurable environmental impact across India.

 

Business Wire India

• A Landmark Registrational Study Aiming to Redefine Outcomes in MSS mCRC Which Represents Approximately 95% of Metastatic Colorectal Cancer Cases
• Colorectal Cancer Has Become the Leading Cause of Cancer-related Death in Adults Under Age 50

 

Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that the first patient has been enrolled in the landmark global phase 3 BATTMAN (CO.33) trial (NCT07152821). This study is evaluating Agenus’ immunotherapy combination of botensilimab (BOT) plus balstilimab (BAL) versus best supportive care in patients with refractory, unresectable microsatellite stable (MSS)/mismatch repair proficient (pMMR) metastatic colorectal cancer (mCRC), a population long considered resistant to immunotherapy.

 

This study is being conducted as a cooperative group trial led by the Canadian Cancer Trials Group (CCTG) from Canada and run across Canada, France, Australia and New Zealand. More than 100 sites will participate across the academic cooperative networks of CCTG, GI Cancer Trials in Australia and France’s Partenariat de Recherche en Oncologie Digestive (PRODIGE) consortium (including Unicancer, GERCOR and FFCD). The BATTMAN (CO.33) trial serves as the registrational-enabling study for BOT+BAL enrolling approximately 830 patients and is expected to complete global enrollment quickly, reflecting the unprecedented investigator and patient enthusiasm worldwide, including strong interest from sites and physicians engaged through Agenus’ paid named patient and French AAC access programs.

 

 

“Enrollment of the first patient in the BATTMAN study marks a key milestone for Agenus and the BOT+BAL program,” said Dr. Steven O’Day, Chief Medical Officer, Agenus. “This study advances our goal of developing effective immunotherapies for patients who currently have few options. We’re grateful to our partners at CCTG, GI Cancer Trials in Australia, and PRODIGE and to the dedicated investigators, site staff, and patients driving this global effort.”

 

 

“Our collaboration with Agenus builds on years of cooperative-group research aimed at bringing immunotherapy benefits to patients with microsatellite-stable colorectal cancer—those historically left without effective options,” said Dr.Chris O’Callaghan, DVM, PhD, Senior Investigator, Canadian Cancer Trials Group. “Earlier CCTG studies suggested that doublet immunotherapy could extend survival even in cold tumors, and the magnitude and durability of responses seen with botensilimab and balstilimab in earlier studies warrant their investigation in a phase 3 trial.”

 

 

“The enthusiasm among investigators has been remarkable—within days of Health Canada submission, leading centers across Canada moved to open the study. We’re eager to advance this global effort and potentially transform outcomes for patients who have exhausted all other treatments,” said Dr. Jonathan Loree, MD, MSc, FRCPC, CO.33 Study Chair.

 

 

About the BATTMAN (CO.33) Trial

 

 

The BATTMAN (CCTG CO.33) (NCT07152821) trial is a global Phase 3, randomized, controlled study evaluating botensilimab (BOT) plus balstilimab (BAL) versus best supportive care in patients with refractory, unresectable microsatellite stable (MSS)/mismatch repair proficient (pMMR) colorectal cancer. Conducted as an international cooperative group study led by the Canadian Cancer Trials Group (CCTG), the trial will enroll approximately 830 patients across more than 100 sites in Canada, France, Australia, and New Zealand. Participating academic networks include CCTG, the GI Cancer Trials, and France’s Partenariat de Recherche en Oncologie Digestive (PRODIGE), sponsored by UNICANCER. This registrational-enabling study is designed to support potential regulatory submissions for BOT+BAL in this difficult-to-treat patient population. Patients interested in learning more about the study, including eligibility and enrollment information, can visit: https://www.ctg.queensu.ca/patients/colorectal-cancer-clinical-trial-co33.

 

 

About Agenus

 

 

Agenus is a leading immuno-oncology company targeting cancer with a comprehensive pipeline of immunological agents. The company was founded in 1994 with a mission to expand patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants. Agenus has robust end-to-end development capabilities, across commercial and clinical cGMP manufacturing facilities, research and discovery, and a global clinical operations footprint. Agenus is headquartered in Lexington, MA. For more information, visit www.agenusbio.com or @agenus_bio. Information that may be important to investors will be routinely posted on our website and social media channels.

 

 

About Canadian Cancer Trials Group (CCTG)

 

 

The Canadian Cancer Trials Group (CCTG) is a cancer clinical trials research cooperative that runs phase I–III trials to test anti-cancer and supportive therapies across Canada, and internationally. Headquartered at Queen’s University, CCTG has supported more than 700 trials enrolling 100,000 patients from 40 countries on 6 continents through a global network of 20,000 investigators and clinical trial staff. CCTG is the Canadian Coordinating Clinical Trial Network for the US NCTN and is a national program of the Canadian Cancer Society. CCTG’s aim is to improve survival and quality of life for all people with cancer. Learn more at cctg.ca.

 

 

About Botensilimab (BOT)

 

 

Botensilimab (BOT) is a human Fc enhanced multifunctional anti-CTLA-4 antibody designed to boost both innate and adaptive anti-tumor immune responses. Its novel design leverages mechanisms of action to extend immunotherapy benefits to “cold” tumors which generally respond poorly to standard of care or are refractory to conventional PD-1/CTLA-4 therapies and investigational therapies. Botensilimab augments immune responses across a wide range of tumor types by priming and activating T cells, downregulating intratumoral regulatory T cells, activating myeloid cells and inducing long-term memory responses.

 

 

Approximately 1,200 patients have been treated with botensilimab and/or balstilimab in phase 1 and phase 2 clinical trials. Botensilimab alone, or in combination with Agenus’ investigational PD-1 antibody, balstilimab, has shown clinical responses across nine metastatic, late-line cancers. For more information about botensilimab trials, visit www.clinicaltrials.gov.

 

 

About Balstilimab (BAL)

 

 

Balstilimab is a novel, fully human monoclonal immunoglobulin G4 (IgG4) designed to block PD-1 (programmed cell death protein 1) from interacting with its ligands PD-L1 and PD-L2. It has been evaluated in more than 900 patients to date and has demonstrated clinical activity and a favorable tolerability profile in several tumor types.

 

 

Forward-Looking Statements

 

 

This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding its botensilimab and balstilimab programs, expected regulatory timelines and filings, and any other statements containing the words “may,” “believes,” “expects,” “anticipates,” “hopes,” “intends,” “plans,” “forecasts,” “estimates,” “will,” “establish,” “potential,” “superiority,” “best in class,” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, among others, the factors described under the Risk Factors section of our most recent Annual Report on Form 10-K for 2024, and subsequent Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission. Agenus cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and Agenus undertakes no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.

 

 

 

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260401039214/en/

 

Business Wire India

Three world-class innovators are the founder licensors of the new Point of Sale (POS) patent pool, covering 2G to 5G technology, which Sisvel has launched today.

 

Huawei, LG Electronics and Nokia have made their standard essential patents (SEPs) reading on cellularly connected POS devices available through the programme, so simplifying access to the increasingly ubiquitous technology.

 

 

Early participation incentives for licensors to join the pool are available until mid-May. Other cellular patent owners not currently in discussions with Sisvel are encouraged to get in touch.

 

 

Ranging from handheld card machines to tablet-based registers, POS devices have transformed customer payment processing. Increasingly, they also offer enhanced capabilities such as inventory management, real-time tracking, advanced analytics and automatic re-ordering.

 

 

Standardised cellular technology is the critical feature that enables POS terminals to function wherever customers are located. The Sisvel POS programme offers an efficient and transparent way for implementers to access the relevant SEPs of the participating patent owners under fair, reasonable and non-discriminatory (FRAND) terms.

 

 

“Cellular technology has revolutionised the payments experience for both purchasers and vendors, and the new Sisvel POS pool will make accessing it more efficient and transparent,” says programme manager Sven Törringer. “As new licensors are expected to join soon, the programme is set to become even more compelling. This is an exciting day for Sisvel and the POS market. We thank Huawei, LG Electronics and Nokia for their leadership.”

 

 

About Sisvel

 

 

Sisvel is driven by a belief in the importance of collaboration, ingenuity and efficiency to bridge the needs of patent owners and those who wish to access their technologies. In a complex and constantly evolving marketplace, our guiding principle is to create a level playing field through the development and implementation of flexible, accessible, commercialisation solutions.

 

 

Sisvel | We Power Innovation

 

 

 

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260401838616/en/

 

Business Wire India

Summer heat, humidity, and strong sunlight can affect how your skin behaves. Sweat, dust, and UV exposure may lead to oiliness, tanning, breakouts, and dullness. Building a simple summer vanity with the right skincare essentials and healthy habits can help keep your skin fresh, protected, and glowing even during the hottest days.

1. Sunscreen is your non-negotiable step

Daily sun exposure can lead to tanning, dark spots, and premature ageing, making sunscreen the most important step in any summer routine. Choose a broad-spectrum sunscreen with SPF 30 or higher and apply it to the face, neck, and other exposed areas 15–20 minutes before stepping outdoors. Reapply every two to three hours, especially if you are sweating or spending extended time in the sun.

Products that combine sun protection with skincare benefits can also simplify your routine. For instance, NIVEA Luminous Even Day Cream SPF 50 helps protect skin with UVA/UVB filters, while Thiamidol works to target dark spots at the source. With hyaluronic acid for hydration and up to 12-hour oil control, it helps maintain a fresh, even-looking complexion during hot and humid weather. It’s a perfect mix of moisturiser & sun protection.

2. Gentle cleansing keeps skin clear

Summer weather increases sweat and oil production, which can clog pores and trigger breakouts. Washing your face twice a day with a mild cleanser helps remove sweat, sunscreen, and pollution without damaging the skin barrier. If your skin feels extra oily in humid weather, light gel-based cleansers can help keep pores clear while maintaining balance.

3. Stay hydrated throughout the day

Hydration plays a major role in maintaining healthy skin during summer. Drinking adequate water throughout the day helps maintain moisture levels and supports overall skin health. Include fruits with high water content, like watermelon, cucumber, oranges, and berries, to keep your body cool and hydrated.

4. Wear breathable fabrics

What you wear can also impact your skin in hot weather. Tight or synthetic fabrics may trap sweat and increase irritation. Opt for loose, breathable fabrics like cotton or linen, which allow air circulation and help prevent sweat rashes and body acne.

5. Avoid peak sun hours when possible

The sun is strongest between 10 AM and 4 PM. When possible, limit prolonged exposure during these hours. Using hats, umbrellas, wearing sunglasses, or seeking shade can reduce UV exposure and help prevent tanning and sunburn.

6. Exfoliate gently, but not too often

Sweat and sunscreen buildup can leave skin feeling dull. Gentle exfoliation once or twice a week can help remove dead skin cells and keep pores clear. Avoid harsh scrubs or excessive exfoliation, which may irritate skin already stressed by heat and sun.

7. Keep your routine simple and consistent

Summer skincare works best when routines are minimal and consistent. Focus on a few essential steps: cleanse, hydrate, protect, and treat specific concerns like pigmentation or acne. A thoughtfully curated summer vanity paired with healthy habits can help your skin stay comfortable, protected, and radiant all season long.